Register Now

The launch of PEGS China: Protein & Antibody Engineering and Development Summit held on April 1-3, 2014 in Shanghai, China was a great success! Over 200 attendees from China, US, Europe and other parts of Asia met to share their latest case studies, explorations and development strategies on new and existing biotherapeutics, including ADCs, bispecifics, alternative scaffolds, T-cell therapies, and of course, mAb biosimilars.

The conference sessions were highly animated with many questions from the audience; the exhibit hall was abuzz with attendees eager to explore new technologies while everywhere around, people were discussing plans for collaborations, making appointments to visit sites in China and most importantly, building relationships through valuable face-to-face meetings.

Here’s a snapshot of the highlights of the event:

  • A packed Plenary Keynote session featuring CHO cell guru Dr Florian Wurm; a successful collaboration case study between Ambrx and Zhejiang Medicines Co. as well as the success story of the first fully human mAb in China
  • Featured presenters Vaughn Himes, EVP of Seattle Genetics delivered a stellar presentation on CMC Strategies for Antibody-Drug Conjugates; Bo Xu, Head of Boehringer-Ingelheim showcased BI’s inroads into China; while Ingo Gorr of Roche Diagnostics expounded the importance of integrating up- and down-stream processing
  • Over 10 Breakout Roundtable Discussions with people sharing challenges, experiences and possible solutions

We’ve already received numerous comments praising the work that was done at the event, but we would still like to hear from you on more specific questions to help us deliver new ideas, and develop the agenda and schedule for 2015. If you would like to share your feedback, or give input for next year’s event, please contact Mimi Langley at mlangley@healthtech.com 

Mark Your Calendar: March 31-April 2, 2015
A big Thank You to all our speakers, sponsors, and exhibitors for your support and contributions, and to all the delegates for your participation. The continued success of this event will largely depend on the dedicated participants that return with us year after year. Save the date to join us again next year in Shanghai, China: March 31-April 2, 2015!

 


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 



Download Brochure
2014 ABA Brochure Icon

About Pegs 


CHI is excited to announce the launch of “PEGS China”. Spurred by the growth in the biopharmaceutical sector in Asia and the demand by our participants and exhibitors to bring higher quality, established and credible conferences to this region, CHI will launch its first Asia PEGS Summit in China in April 2014. The event will focus on topics of greater relevance and interest to the China/Asia biopharmaceutical industry, including protein and antibody engineering, protein expression, analytical techniques and CMC strategies.

“PEGS Summit” has grown in leaps and bounds driven by the growth in biologics worldwide. Attracting over 1600 participants at this year’s 9th Annual PEGS Summit in Boston, and record attendance expected at the upcoming PEGS Europe event being held in Lisbon, “PEGS” is CHI’s flagship biologics event, and considered the industry leading event.

 

2014 Scientific Programs 


 

Premier Sponsors 

Malvern small logo 

OriGene 

View All Sponsors > 

View Media Partners > 

Sponsorships & Exhibits > 

Promote your company’s latest technology and/or solution at PEGS CHINA. A limited number of agenda presentations (as part of a sponsorship package), exhibit space, branding, and promotional opportunities are available.

 

 

HOTEL & TRAVEL

Hotel and Travel

Shanghai, China

COLLEAGUE TESTIMONIALS


“PEGS is the leading protein and antibody engineering conference worldwide. The event covers all scientific aspects from design and engineering to final product characterization. I come to PEGS every year as often talks are about new and exciting work that has never been shown before”

- PEGS Boston 2013 Participant

AUDIENCE PROFILE


Scientists, engineers and executives working in

  • protein/antibody engineering
  • protein/antibody expression
  • cell line engineering
  • ADCs and bispecifics
  • biosimilars development
  • immunogenicity
  • formulation
  • analytical chemistry
  • analytical method development
  • up- and down-stream processing
  • technical services
  • manufacturing sciences and technology
  • facilities design and technologies